Tag: ALS (Lou Gehrig’s Disease)
Alpha-Linolenic Acid Levels Inversely Linked to Risk of Death in ALS
Higher levels of eicosapentaenoic acid and linoleic acid also associated with reduced risk of death during follow-up
Allopurinol May Cut Risk for Neurodegenerative Diseases
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
FDA Approves Drug for Rare Form of ALS
Agency approved the drug based on evidence of a reduction in plasma neurofilament light; no evidence the drug slowed the disease
Hospital-Treated Infections Earlier in Life Tied to Alzheimer, Parkinson Disease Risk
Association found for Alzheimer and Parkinson disease cases diagnosed before 60 years of age
Occupational Exposures Tied to ALS Risk
Greatest risks seen with self-reported occupational metals exposure
In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review
Medication combines a dietary supplement used in traditional Chinese medicine with an existing prescription drug for liver disorders
FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote
But getting the drug, known as Albrioza, approved is a rallying cause for patients, their families, and members of Congress
New ALS Drug Approved in Canada While Still Under FDA Review
Last month, 38 U.S. doctors who treat ALS patients sent a letter urging the FDA to approve the drug
FDA Advisory Panel Narrowly Votes Against New ALS Drug
Panelists said they hoped results of a larger study, now underway, would provide more evidence on the drug
FDA Reviewers Give Thumbs Down to New ALS Drug
Agency said results were 'not persuasive,' citing missing data, mistakes in enlisting patients, other issues
